HNMPA is a cell impermeable tyrosine kinase inhibitor that blocks receptor serine and tyrosine phosphorylation, including insulin receptor tyrosine kinase activity. It does not affect protein kinase C or cyclic AMP-dependent protein kinase activities. HNMPA inhibits the insulin-stimulated autophosphorylation of the 95-kDa β-subunit of the insulin receptor with an IC50 value of 200 μM in vitro.
A selective insulin receptor tyrosine kinase inhibitor
Insulin receptor tyrosine kinase (IRTK) inhibitor.
[1]. baltensperger k, lewis re, woon cw, et al. catalysis of serine and tyrosine autophosphorylation by the human insulin receptor. proc natl acad sci u s a. 1992 sep 1;89(17):7885-9.
[2]. moon mj, kim hy, park s, et al. insulin contributes to fine-tuning of the pancreatic beta-cell response to glucagon-like peptide-1. mol cells. 2011 oct;32(4):389-95.
